X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
TEVA PHARMA
Dec-13
AJANTA PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7202,658-   
Low Rs1,1032,309-   
Sales per share (Unadj.) Rs194.61,525.2-  
Earnings per share (Unadj.) Rs45.295.3-  
Cash flow per share (Unadj.) Rs50.3218.6-  
Dividends per share (Unadj.) Rs8.0083.41-  
Dividend yield (eoy) %0.63.4 16.9%  
Book value per share (Unadj.) Rs132.01,694.2-  
Shares outstanding (eoy) m88.77848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.6 445.5%   
Avg P/E ratio x31.226.1 119.8%  
P/CF ratio (eoy) x28.111.4 247.0%  
Price / Book Value ratio x10.71.5 729.4%  
Dividend payout %17.787.5 20.2%   
Avg Mkt Cap Rs m125,2992,105,694 6.0%   
No. of employees `000NA44.9 0.0%   
Total wages/salary Rs m2,5700-   
Avg. sales/employee Rs ThNM28,777.2-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM1,797.7-  
INCOME DATA
Net Sales Rs m17,2751,293,392 1.3%  
Other income Rs m1660-   
Total revenues Rs m17,4421,293,392 1.3%   
Gross profit Rs m5,807354,196 1.6%  
Depreciation Rs m451104,546 0.4%   
Interest Rs m4925,404 0.2%   
Profit before tax Rs m5,474224,246 2.4%   
Minority Interest Rs m01,019 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-147,205 0.0%   
Tax Rs m1,460-2,738 -53.3%   
Profit after tax Rs m4,01480,797 5.0%  
Gross profit margin %33.627.4 122.8%  
Effective tax rate %26.7-1.2 -2,184.4%   
Net profit margin %23.26.2 372.0%  
BALANCE SHEET DATA
Current assets Rs m7,639873,552 0.9%   
Current liabilities Rs m2,715761,812 0.4%   
Net working cap to sales %28.58.6 329.9%  
Current ratio x2.81.1 245.4%  
Inventory Days Days4391 47.6%  
Debtors Days Days7996 82.0%  
Net fixed assets Rs m6,914422,450 1.6%   
Share capital Rs m1773,184 5.6%   
"Free" reserves Rs m11,4420-   
Net worth Rs m11,7211,436,714 0.8%   
Long term debt Rs m149661,340 0.0%   
Total assets Rs m14,8142,955,816 0.5%  
Interest coverage x112.99.8 1,149.3%   
Debt to equity ratio x00.5 2.8%  
Sales to assets ratio x1.20.4 266.5%   
Return on assets %27.43.6 763.3%  
Return on equity %34.25.6 609.0%  
Return on capital %46.54.9 943.6%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Net fx Rs m8,7440-   
CASH FLOW
From Operations Rs m3,264206,100 1.6%  
From Investments Rs m-2,093-73,029 2.9%  
From Financial Activity Rs m-1,186-247,231 0.5%  
Net Cashflow Rs m-15-114,160 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.67 Rs / USD

Compare AJANTA PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare AJANTA PHARMA With: JUBILANT LIFE SCIENCES  MERCK LTD  AUROBINDO PHARMA  GSK PHARMA  ORCHID PHARMA LTD  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS